- Home
- PRAX
as 08-15-2025 4:00pm EST
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 950.8M | IPO Year: | 2020 |
| Target Price: | $102.00 | AVG Volume (30 days): | 578.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.70 - $91.83 | Next Earning Date: | 08-04-2025 |
| Revenue: | $7,765,000 | Revenue Growth: | 338.45% |
| Revenue Growth (this year): | -94.9% | Revenue Growth (next year): | 3567.38% |
Latest Praxis Precision Medicines Inc. News
PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing
Insider Monkey
2 months ago
Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX)
GlobeNewswire
2 months ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Energy Global
2 months ago
TPG Rise Climate acquires Aurora Energy Research
GlobeNewswire
2 months ago
Form 8.3 - Assura Plc
PR Newswire
2 months ago
BAE Systems awarded $30 million from U.S. Navy for Identification Friend or Foe AN/APX-123A(V) Common Transponder
GlobeNewswire
2 months ago
Media Advisory – Canada’s food workers union sues Health Canada over pesticide safety failures
Business Wire
2 months ago
Net Asset Value(s)
PR Newswire
2 months ago
Makera Wins Desktop CNC Machine Company of the Year Award
Compare PRAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.